logo
Plus   Neg
Share
Email

FDA Panel Backs Lucentis For Treatment Of Diabetic Macular Edema

Genentech, a member of the Roche Group (RHHBY.PK), said Thursday that the U.S. Food & Drug Administration Dermatologic & Ophthalmic Drugs Advisory Committee voted 10-0 to recommend approval of the 0.3 mg dose of Lucentis for treatment of diabetic macular edema.

The majority of the panel also recommended the 0.5 mg dose.

The panel's recommendation was based on a review of data from Genentech's Phase III trials, RIDE and RISE, which evaluated the efficacy and safety of Lucentis in people with diabetic macular edema. The primary endpoint was the percentage of patients who could read an additional 15 letters or more on the standard eye chart after 24 months of treatment compared to the percentage in a control group.

The FDA is expected to make a decision regarding the supplemental Biologics License Application for Lucentis in diabetic macular edema by August 10.

The FDA generally follows advisory committee recommendations, although it is not bound to do so.

Diabetic macular edema is an eye condition in people with diabetes characterized by retinal swelling and blurred vision. It is a major cause of vision loss and blindness estimated to affect more than 560,000 people in the United States. The current standard of care for diabetic macular edema in the U.S. is laser surgery, which mainly serves to slow the progression of vision loss and help stabilize vision.

Lucentis was first approved by the FDA for treatment of wet age-related macular degeneration in 2006 and for macular edema following retinal vein occlusion in 2010.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart is ditching its dress code policy and is testing a new dress code that will allows "associates" to wear blue denim and shirts of any solid color. The updated dress coded guidelines now allow employees to wear blue "jeggings" and blue jeans and shirts of any solid color, according to a Walmart... Canadian investment firm Fairfax Financial Holdings Ltd. has submitted a "stalking horse" bid worth C$300 million, or $237 million, for the Canadian unit of Toys "R" Us, according to court documents. A stalking horse bid is an initial bid on the assets of a bankrupt company. The bankrupt company will choose an entity from a pool of bidders who will make the first bid on its assets. The car rental market in the U.S. is consolidating as large car rental companies are buying smaller, local companies to expand their portfolio of premium and value brands. The key players in the U.S. market include Enterprise Holdings, Hertz Global Holding and Avis Budget Group. Let's take a look at some of the best and worst car rental companies in the U.S.
Follow RTT